There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Acasti Pharma (ACST – Research Report), ImmunoPrecise Antibodies (IPA – Research Report) and Evotec AG (EVO – Research Report) with bullish sentiments.
Acasti Pharma (ACST)
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Acasti Pharma today and set a price target of $12.00. The company’s shares closed last Tuesday at $2.38, close to its 52-week low of $2.04.
According to TipRanks.com, Livnat is a 2-star analyst with an average return of
Currently, the analyst consensus on Acasti Pharma is a Moderate Buy with an average price target of $12.00.
See today’s best-performing stocks on TipRanks >>
ImmunoPrecise Antibodies (IPA)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on ImmunoPrecise Antibodies today and set a price target of $9.00. The company’s shares closed last Tuesday at $3.01, close to its 52-week low of $2.35.
According to TipRanks.com, Ramakanth has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ImmunoPrecise Antibodies with a $9.00 average price target.
Evotec AG (EVO)
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Evotec AG, with a price target of $12.00. The company’s shares closed last Tuesday at $11.91.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evotec AG with a $13.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACST:
